Introduction
============

Human immunodeficiency virus type 1 (HIV-1) currently affects more than 37 million people worldwide with approximately 2 million people that are newly infected every year ([@B102]). Antiretroviral therapy (ART) has been shown to inhibit active viral replication, driving viral loads to undetectable levels ([@B70]). While ART has transformed the clinical management of HIV-1 disease, it has not led to a cure of this disease due to the development of a residual level of virus often referred to as the latent reservoir ([@B54]). In an attempt to prevent or more recently treat infection entirely, a vaccine has been in development for more than three decades. While there have been numerous HIV-1 vaccine clinical trials, there has yet to be one that demonstrated significant clinical success. The only clinical trial to demonstrate some level of success was the RV144 trial ([@B94]). Due to continued difficulties in continuing traditional vaccine strategies, researchers have turned to a number of alternative methods including gene editing to achieve a functional or sterilizing cure.

HIV-1 infects cells that express CD4 and the co-receptors CCR5 or CXCR4 ([@B70]). The CD4, CCR5, CXCR4 axis is considered the classical route of HIV-1 entry, although there is a body of literature that demonstrates HIV-1 employs a number of methods to get into target cells ([@B64]). While CD4+ T cells represent the primary target of HIV-1, macrophages are also readily infected by HIV-1 ([@B7]). It has been shown that HIV-1 can infect macrophages in a CD4 independent manner, leading to endocytosis of the virus ([@B49]; [@B45]). In addition, there have been studies that have revealed a CD4 and CCR5 or CXCR4 independent method for HIV-1 infection of macrophages ([@B45]). This mechanism of entry has been largely attributed to the phagocytic nature of macrophages. While it is rare to have dendritic cells (DCs) infected by HIV-1, it is well established that HIV-1 can bind and stay bound to a DC receptor known as DC-SIGN ([@B77]). In addition, it has been shown that CD169 plays a significant role in mediating HIV-1 capture by DCs. As HIV-1 buds from an infected cell it incorporates a glycosphingolipid (GSL) with a terminal α2,3 sialic acid residue known as GS3. GS3 is then able to bind to CD169 which has been shown to be upregulated in the presence of interferon (IFN) thereby contributing to cell-to-cell transmission ([@B47]). These interactions allow DCs that have HIV-1 bound on the surface to interact with uninfected T cells, leading to an enhancement of infection, through cell-to-cell transmission.

To date, one patient, "the Berlin patient," is considered cured of HIV-1. This patient received a bone marrow transplant from a donor who was homozygous for a CCR5 mutation known as CCR5Δ32. While the exact mechanism of how this patient defeated HIV-1 is still under investigation, it is largely believed that the CCR5 mutation was a key factor ([@B132]). Although, it should be noted that this patient did have CXCR4-utilizing virus but surprisingly a rebound of this virus has not been observed. An additional transplant study was able to deep sequence the provirus from an HIV-1-infected patient. The gp120 V3 region from this patient was cloned into an HIV-1 backbone and it was shown that this virus was able to infect PBMCs through CXCR4 ([@B115]). After allogenic transplantation from a CCR5Δ32 donor, a CXCR4 utilizing virus rebounded in that patient. This has spawned research efforts to utilize gene editing technologies to manually reconstruct the CCR5Δ32 mutation ([@B107]). Ideally this research would be aimed at either editing hematopoietic stem cells to give rise to cells that are naturally resistant to HIV-1 infection or edit peripheral blood mononuclear cells (PBMCs) and infuse them back into the patient.

Three main gene editing technologies have been used to edit CCR5 and CXCR4. These include zinc finger nucleases (ZFN), transcription activator--like effector nucleases (TALENs), and the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system ([@B120]; [@B125]; [@B130]; Figure [1](#F1){ref-type="fig"}). While these systems aim to edit the genome, they go about it in two very different ways. ZFNs are made up of protein modules that recognize their target DNA sequence, as previously reviewed ([@B55]). Attached to these sequence modules are Fok1 endonucleases which are responsible for catalyzing the double stranded break (DSB) in the target DNA ([@B133]). TALENs act very similarly to ZFNs by having amino acid repeats that are capable of binding DNA and utilizing Fok1 as the nuclease effector ([@B57]). The CRISPR/Cas9 system works by utilizing a custom designed guide RNA (gRNA) sequence that complexes with the Cas9 endonuclease. The gRNA is broken into two main components. The protospacer is a 20 base pair (bp) sequence that binds to target DNA with sequence complementarity. The scaffold component has been shown to allow the gRNA to bind with the Cas9 endonuclease. Once the gRNA and the Cas9 have bound together to form a ribonucleoprotein complex, the Cas9 enzyme binds to a protospacer adjacent motif (PAM), normally an NGG sequence for Streptococcus pyogenes Cas9. Once the Cas9 has bound, the gRNA is able to bind with complementarity to its target site and a DSB will occur ([@B34]).
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There have been numerous studies performed with ZFN to edit the CCR5 gene in an attempt to stop HIV-1 infection. *In vitro* studies have shown that editing the CCR5 locus limits the number of cells HIV-1 can infect ([@B118], [@B117]; [@B69]). Moreover, there have been a limited number of *in vivo* studies using ZFN to edit CCR5 ([@B120]; [@B128]). These studies were able to show that even with successful gene editing HIV-1 was able to replicate, albeit to a lesser extent. While editing CCR5 confers resistance to CCR5-utilizing viruses, it doesn't confer resistance to CXCR4-utilizing viruses. These results have led to a number of studies aimed at editing CXCR4. Preliminary results have shown that editing CXCR4 conferred resistance to X4 virus with minimal cytotoxicity ([@B51]; [@B130]).

Editing studies targeting CCR5 and CXCR4 have brought to light the problem of gene editing efficiency. This efficiency problem is highlighted in studies, utilizing humanized mouse models. These studies have shown that HIV-1 was able to replicate at the early time points but replication declines over time when compared to the untreated control. It is now believed that HIV-1 will replicate in cells that were not successfully modified and when those target cells decrease in number with time, there will be a simultaneous expansion in the number of edited cells ultimately limiting the infection ([@B125]). Data supporting this model of conferred resistance has been observed using CRISPR, ZFN, and TALEN therapeutic approaches. These gene editing technologies have been shown to successfully edit both CCR5 and CXCR4 in a population of cells. While these results are promising, an increase in gene editing efficiency for both co-receptors and enhancements to existing delivery systems will be necessary for these therapeutic approaches to be successful. In this review, we examine studies that have utilized different gene editing technologies to edit CCR5 or CXCR4 and discuss how different mechanisms of HIV-1 infection can be inhibited by editing the co-receptors needed for HIV-1 infection.

Cellular Components That Are Involved in HIV-1 Entry Are Potential Targets to Stop Infection
============================================================================================

To date, the process of HIV-1 entry has been dissected into three major steps: (1) HIV-1 gp120 recognizes host receptor CD4 followed by a conformational change of gp120 ([@B71]; [@B99]; [@B65]). (2) The restructured gp120 is able to recognize host co-receptor CXCR4 ([@B87]) or CCR5 ([@B4]; [@B21]; [@B28]; [@B33]; [@B35]; [@B38]), which gives rise to the exposure of the hydrophobic fusion peptide on HIV-1, referred to as gp41. (3) The formation of a six-helix bundle using three gp41 subunits brings the plasma membrane and HIV-1 Env in close proximity, completing the membrane fusion event ([@B19]; [@B119]; [@B40]; [@B76]). Intervention in any step of the HIV-1 entry process may establish an effective barrier to prevent new infections ([@B18]; [@B108]; [@B89]). Indeed, research using different strategies to inhibit all three steps of the HIV-1 entry cycle have achieved resounding success. CD4 or CD8 molecules have been genetically engineered and chimerically coupled with the zeta-chain of the T-cell receptor; and as constructed, the expression of chimeric CD4 receptor molecules upon the recognition of HIV-1 Env would activate the effector function of these T cells and stop the new infection ([@B95]; [@B126]). This strategy has led to two clinical trials that resulted in minimal impact on CD4 count and viral load in all patients examined in the study; however, a significant reduction of the HIV-1 reservoir was demonstrated in CD4 zeta-modified autologous CD4 and CD8 T cells ([@B79]; [@B116]; [@B26]). The possibility of interrupting the formation of the six-helix bundle during membrane fusion has also been explored as well. Research focused on peptide inhibitors has led to the development of enfuvirtide, approved by the FDA in 2003, this drug has been shown to prevent fusion and subsequent viral entry ([@B36]).

Most New Infections Are Caused by CCR5- Rather Than CXCR4-Utilizing HIV-1
=========================================================================

Studies have shown that HIV-1 transmission involves a substantial bottleneck in the number of viral quasispecies that enter the PBMC compartment following a heterosexual genital tract transmission event with only a small number of quasispecies and often a single genotype existing in the periphery after the initial month of infection. Subsequently, genetic diversity of the HIV-1 viral quasispecies rebounds greatly during symptomatic and chronic infection prior to initiation of ART ([@B122]; [@B123]; [@B134]; [@B97]). More specifically, a number of experimental assays were used to determine that up to 80% of heterosexually transmitted HIV-1 infections worldwide were established by a single HIV-1 genotype in each infected individual, known as the transmitter founder virus ([@B29]; [@B58]; [@B1]; [@B48]). The low diversity of transmitted virus in newly infected individuals has important implications for vaccine development, with the intention of developing an HIV-1 vaccine that could be broadly protective across the genetic diversity of transmitted/founder virus population across a large number of individuals. Interestingly, additional studies have suggested that most of the transmitter/founder viruses utilize CCR5 as the co-receptor for cell entry ([@B58]). Clinical samples from early HIV-1 infections have shown that HIV-1 variants predominantly use CCR5 exclusively during the course of HIV-1 infection ([@B16]; [@B81]). It is also known that specific HIV-1 strains utilize CXCR4 as the entry co-receptor ([@B13]). However, less than 1% of infected individuals possessed HIV-1 that was exclusively CXCR4-utilizing ([@B16]; [@B81]). A more recent clinical trial of the CCR5 inhibitor vicriviroc demonstrated that 50% of subjects had CCR5-utilizing virus, whereas CXCR4-utilizing viruses were only found in 4% of involved subjects. The other 46% contained both CXCR4- and CCR5-utilizing viruses ([@B121]). These clinical studies highlight the importance of CCR5 for the course of HIV-1 infection from the point of transmission to chronic infection. It has also been implied that the stochastic process and selection pressure may lead to a shift in co-receptor usage that is distinct for each patient.

Gene Editing to Engineer Cells Resistant to HIV-1 Infection
===========================================================

Research efforts aimed at curing HIV-1 infection are currently focused on two curative strategies: functional and sterilizing cures ([@B114]; [@B59], [@B60]). A sterilizing cure would entail the removal of provirus from all latent reservoir cells, thus curing the patient of HIV-1 altogether ([@B106]; [@B59], [@B60]). A functional cure would enable patients to suppress viral replication in the absence of ART without accomplishing complete eradication of the latent proviral reservoir ([@B114]; [@B59]). Rapidly advancing techniques in gene editing offer a promising approach to both of these general curative strategies ([@B59], [@B60]). Gene editing techniques capable of highly specific excision offer a compelling approach to the development of a sterilizing cure via complete proviral removal ([@B74]; [@B23], [@B24], [@B25]; [@B52]). Toward a functional cure, HIV-1 co-receptors CXCR4 and CCR5 are considered therapeutic targets for disruption of viral replication and modern gene editing nucleases have the capability to disrupt cell-surface co-receptor expression ([@B59], [@B60]). Enthusiasm for CCR5 as a therapeutic target has been bolstered by the long-term functional suppression of viral gene expression in the Berlin patient. The patient's functional cure is attributed to an immune cell transplant containing the CCR5Δ32 mutation, a truncated CCR5 protein with ablated expression on the cell surface ([@B5]; [@B72]). Attempts to suppress HIV-1 co-receptors to curb viral proliferation did not begin with gene editing nucleases. RNA interference (RNAi) using short-hairpin RNAs (shRNA) was an approach used before gene editing technologies were available ([@B96]; [@B104]). The lentiviral vector expressing CCR5-shRNA has been developed to transfect primary human lymphocytes using oligofectamine. The transfected cells showed 60% to 96% reduction in CCR5 expression ([@B6]). A study using a humanized mouse model with human hematopoietic progenitor stem cells transduced by CCR5-shRNA-expressing lentivirus showed that there was no production of p24 in an *ex vivo* test after 12 days of infection with CCR5-tropic HIV-1 NL4-3 in CCR5-shRNA+ splenocytes ([@B104]). However, gene editing nucleases have a distinct advantage over RNAi techniques. RNAi must be continuously expressed in order to continuously suppress CCR5 expression on the cell surface. Gene editing nucleases need only be expressed transiently in order to disrupt CCR5 expression indefinitely ([@B50]).

Zinc Finger Nucleases: Targeting CCR5
=====================================

Zinc finger nucleases (ZFNs) emerged early in the field of gene editing with the novel capability to target specific genomic sites ([@B12]; [@B93]; [@B112]; [@B11]). Modification of ZFNs introduced a structural requirement such that the nucleases could only cleave when paired as a heterodimer which improved specificity of ZFN sequence targeting ([@B78]). The progression of this technology naturally led to attempts to edit the genes expressing CCR5 in CD4+ T cells. Early successes, demonstrating the feasibility of this approach have focused on specifically targeting disruption of the gene encoding CCR5 in human CD4+ T cells or hematopoietic stem/progenitor cells (HSPCs). The strategy relies on stable transplantation of modified cells into an organism and the preferential survival of modified cells when challenged with CCR5-utilizing HIV-1 virus. Multiple studies report measurable reduction of viral load following treatment in animal models as well as clinical trials ([@B91]; [@B50]; [@B107]). Interestingly a number of the *in vitro* and *in vivo* results came after the start of clinical trials. A recent study successfully disrupted CCR5 using ZFN in primary human CD4+ T cells. Adenovirus Ad5/35 transduction was examined in HIV-1-infected patient-derived primary CD4+ T cells and revealed a ZFN-induced modification efficiency of 35.6% on CCR5 alleles ([@B91]). Mice engrafted with modified cells showed significantly reduced viral loads at 30 and 50 days compared to those engrafted with wild-type cells ([@B91]). In another study, ZFNs were used to disrupt the gene for CCR5 in human CD34 HSPC cells ([@B50]). ZFN expression plasmid was introduced through nucleofection in human hematopoietic stem cells targeting CCR5 and modified a mean of 17% of CCR5 alleles in CD34+ HSPCs ([@B50]). Mice transplanted with the modified HSPCs showed a selective advantage for successfully edited CD4^+^ T cells when infected with CCR5-utilizing HIV-1. At peak viremia, 6 weeks post-infection, mice transplanted with ZFN-modified cells showed a significantly reduced systemic viral load. Furthermore, mice that were administered a ZFN-modified transplant but were infected with a CXCR4-utilizing HIV-1 strain did not demonstrate an elevated resistance to infection. This supports the understanding that the mechanism of conferred resistance is CCR5-dependent ([@B50]). In addition, this study highlights the fact that modified CCR5-deficient HSPCs are potentially capable of replenishing the immune system with HIV-1 resistant cells providing a sustained therapeutic effect ([@B50]).

Transcription Activator-Like Effector Nucleases: Targeting CCR5
===============================================================

Transcription activator-like effector nucleases (TALENs) are another class of gene editing technology being applied to HIV-1 co-receptor disruption ([@B127]; [@B56]; [@B129]). TALENs are comprised of a non-specific nuclease, FokI, guided by customizable binding domains ([@B59]). Some studies have found that TALENs exhibit an editing efficiency comparable to ZFNs when targeting CCR5 but caused less cytotoxicity with fewer off-target cleavage events ([@B83], [@B82]; [@B59]). One such study tested an array of TALENs designed to target the CCR5 gene by transfecting human primary CD4+T cells and GHOST-CCR5-CXCR4 (a reporter cell line for HIV-1 infection). The most favorable TALEN of those examined exhibited higher specificity and lower cytotoxicity than some ZFNs that have already moved to clinical trials ([@B91]; [@B107]). In particular, CCR2 has a high degree of homology with CCR5 and sequence analysis of PCR amplicons expressing the target regions for the TALENs and ZFNs 48 h post-transfection, showed significant mutations in the CCR2 region of the ZFN-treated cells. In contrast, no mutations were detected in the TALEN-treated cell population ([@B103]). An additional study also showed that particularly high cleavage efficiency can be achieved using TALENs *in vitro* ([@B46]). Moreover, engineered TALENs were used to generate the CCR5Δ32 mutation *in vitro* using CD4^+^ U87 cells and achieved a cleavage efficiency greater than 50% without selective pressure ([@B129]). Even so, there is mounting evidence that clustered regulatory interspaced short palindromic repeat (CRISPR)-associated 9 (Cas9) (CRISPR/cas9) gene editing system (discussed in more detail below) is an even more effective gene editing tool than TALENs or ZFNs ([@B60]). A study was performed to compare these different gene editing platforms and found that CRISPR efficiency for generating the CCR5Δ32 mutation via biallelic disruption in induced pluripotent stem cells (iPSCs) was more than twice as effective when compared to TALENs ([@B127]).

Clinical Trials of CCR5 Gene Editing
====================================

Published results from clinical trials of CCR5 have primarily focused on the use of ZFN for CCR5 editing and began before a number of the mechanistic studies from ZFNs and TALENs were performed and published (Figure [2](#F2){ref-type="fig"}). In 1996, Samson and colleagues reported that a 32-base-pair deletion mutant of CCR5 (CCR5Δ32) confers resistance to HIV-1 infection in CD4^+^ cells ([@B98]). Early efforts to exploit the CCR5Δ32 mutation were focused on adoptively transferred CCR5Δ32 allogeneic hematopoietic stem cells as a potential therapy ([@B17]; [@B41]; [@B63]). Previous attempts of *ex vivo* CCR5 modification on CD4^+^ T cells or HSCs have utilized a CCR5-targeted ribozyme alone or with combined RNA interference of HIV-1 viral genes ([@B31]). The clinical trial demonstrated an average of 0.14% of CCR5-modified cells among the infused cell populations. Permanent DNA-level modifications of CCR5 using ZFN have been rapidly adapted in human primary T cells or HSCs ([@B91]; [@B50]). The CCR5-modified cells were engrafted in a number of mouse models and it was demonstrated that up to 50% of CCR5 alleles were genetically disrupted. The success of *in vitro* studies has led to clinical trials. Tebas et al., firstly demonstrated the ZFN-directed CCR5 gene editing on patient-derived CD4 T cells from HIV-1-infected patients ([@B107]). They observed a 28% modification efficiency and reconstitution efficiency of 13.9% of circulating CD4^+^ T cells after transfusion. The decline in circulating CCR5-modified cells was significantly slower than endogenous T cells during the period of ART interruption, indicating that CCR5-modified cells conferred resistance to HIV-1 infection. A phase 1 study of this regimen has mostly been completed with or without additional administration of cyclophosphamide before transfusion ([ClinicalTrials.gov](https://clinicaltrials.gov) Identifier: NCT02388594, NCT00842634, NCT01252641, NCT01044654, NCT02225665). Another clinical trial using CCR5-disrupted HSPCs followed by autologous engraftment after 2 or 3-day administration of busulfan has been estimated to be complete by July 2018 ([ClinicalTrials.gov](https://clinicaltrials.gov) Identifier: NCT02500849). The non-randomized phase 1 study will demonstrate further potential of CCR5-modified hematopoietic CD34+ stem/progenitor cells with respect to the control of HIV-1 infection in patients. While there have been no reported side effects from knocking out CCR5, there are reports that infection with flaviviruses in a CCR5 deficient host result in a higher probability of symptomatic infection ([@B44]).

![Timeline of CCR5 genetic editing. History of studies uncovering the CCR5Δ32 mutation, and landmark investigations modifying the CCR5 receptor.](fmicb-09-02940-g002){#F2}

CRISPR Targeting CCR5
=====================

Clustered regularly interspaced short palindromic repeat (CRISPR)-associated 9 (Cas9) (CRISPR/cas9) is a third class of gene editing tools. Optimization of the CRISPR/Cas9 system has progressed recently demonstrating greater specificity and cleavage efficiency than the ZFN and TALEN systems ([@B39]; [@B111]; [@B60]). A recent study found that CRISPR efficiency for generating the CCR5Δ32 mutation via biallelic disruption in induced pluripotent stem cells (iPSCs) was more than twice as effective when compared to TALENs ([@B127]). More recently, a study compared the performance of the TALENS and CRISPR/Cas9 systems. They concluded that CRISPR/Cas9 outperformed TALENs when targeting the same region of the CCR5 gene. CRISPR/Cas9 showed greater efficiency in both delivery and editing performance *in vitro* ([@B85]).

The CRISPR/Cas9 system offers a distinct advantage over other gene-editing nucleases. Adaptation of CRISPR/Cas9 targeting is simple compared to adjustments to the ZFN and TALEN systems. Changing the cleavage target of CRISPR/Cas9 requires only a change in gRNA sequence. ZFN and TALEN systems require a redesigned protein binding domain in order to change cleavage target sequences ([@B42]; [@B88]; [@B60]). This becomes an important consideration from a design perspective. Overall, clinical trials involving ZFN notwithstanding, CRISPR-Cas9 has been the most promising of the gene editing technologies available for the ablation of HIV-1 co-receptors on susceptible cells for HIV-1 infection.

Additional studies have also demonstrated that CRISPR/Cas9 can be used to ablate HIV-1 co-receptor expression. CRISPR/Cas9 was delivered to CD4+ T cells *in vitro* using a lentiviral vector. Modified cells showed resistance to CCR5-utilizing virus and a selective advantage over wild-type cells ([@B118]). Several studies have also reported successful inhibition of CXCR4 expression and a resultant increase in HIV-1 resistance *in vitro* ([@B51]; [@B69], [@B68]; [@B117]). Recently, a study reported the successful ablation of both the CCR5 and CXCR4 co-receptors *in vitro*. CRISPR/Cas9 mediated editing yielded biallelic disruption of both co-receptors in 9% of modified GHOST CXCR4+ CCR5+ cells ([@B130]).

Despite the promising aspects of gene editing in general and CRISPR/Cas9 in particular, challenges remain. CRISPR/Cas9 has shown great promise but lacks extensive animal model validation that has been achieved with ZFNs. A recent study has been reported using the CRISPR/Cas9 system to edit CCR5 in HSPCs with subsequent use of those HSPCs to engraft a humanized mouse model. CRISPR/Cas9 modified cells conferred resistance to a strain of CCR5-utilizing virus that was comparable to equivalent ZFN strategies ([@B125]). Whether the transplantation of autologous HSPC cells with nuclease-modified CCR5 and CXCR4 genes can be implemented to induce sustainable cell counts of HIV-1 resistant cells thereby precluding the need for ART for an extended period, remains to be seen. To be effective, the strategy of transplanting co-receptor deficient cells to resist propagation of HIV-1 infection must result in a sustainable population of such resistant cells. HSPCs therefore, are the most viable choice for long-term sustainable resistance because they are capable or replenishing the supply of HIV-1 resistant immune cells. However, CXCR4 has been shown to be critical for engraftment of human stem cells into mice ([@B90]).

Zinc Finger Nucleases: Targeting CXCR4
======================================

The majority of published studies investigating HIV-1 co-receptor editing using ZFNs have focused on CCR5. However, the same approach has been applied to editing CXCR4 with some success ([@B131]; [@B30]). A study compared shRNA suppression of CXCR4 to targeted ZFN disruption of CXCR4 in human CD4^+^ T cells ([@B131]). They found ZFN disruption to be the more effective technique. Although lentiviral-vector delivered shRNA was able to suppress expression of CXCR4 on the cell surface, shRNA-expressing cells remained susceptible to viral entry *in vitro*. ZFN-modified CXCR4-deficient cells, by contrast, demonstrated selective advantage when challenged with HIV-1 infection both *in vitro* and *in vivo*. These cells also conferred HIV-1 resistance to engrafted mice ([@B131]). Another study was able to advance this technology by successfully inactivating both CCR5 and CXCR4 in human CD4^+^ T cells. The dual edited cells were shown to have a selective advantage when confronted with CCR5- and CXCR4-utilizing strains of HIV-1 both *in vitro* and after being engrafted into humanized mice ([@B30]).

The Possibility of Clinical Trials Involving the Use of CXCR4 Gene Editing in Humans
====================================================================================

Although previous studies have shown great potential of CCR5 as the target of preventing HIV-1 infection, it is worthy to note that the inhibition of the CCR5-binding site or CCR5 mutants cannot prevent X4-utilizing HIV-1 from infecting cells. A recent report demonstrated a pre-existing CXCR4-utilizing HIV-1 variant in a patient that acquired an allogeneic transplantation of CCR5-knockout stem cells ([@B115]). The CXCR4-utilizing HIV-1 variant was shown to be highly replicative and rapidly rebounded after allogeneic transplantation. Therefore, the examination of CXCR4 modification is of importance in order to block infection by both CCR5- and CXCR4-utilizing viruses. Recently, a study generated dual-modified CCR5 and CXCR4 human primary CD4+ T cells ([@B30]). The successful engraftment followed by the protection from CCR5- or CXCR4-utilizing HIV-1 viruses in a humanized mouse model demonstrated that the gene editing for CXCR4 may enhance the establishment of comprehensive protection from dual tropic viruses or patients carrying both R5 or X4 viruses. Another study further utilized the CRISPR/Cas9 system to increase the specificity and efficacy of CXCR4 ablation on Ghost-X4 T cells and macaque primary CD4+ T cells. The potential of CCR5-modified cell therapy can be attributed to the low toxicity of homozygous modification, which may be due to the existence of redundant chemokine receptors for each of the ligands recognized by CCR5 as previously reviewed ([@B75]). However, there might be substantial concerns to genetically modify CXCR4 with respect to hematopoietic stem cells. CXCR4 has been shown to be embryonic lethal with homozygous mutations in a murine model ([@B135]). It is also suggested that CXCR4 plays a role with respect to the retention of hematopoietic progenitor cells in the bone marrow ([@B15]). The downstream effect of CXCR4 ablation will require further examination and these studies will determine whether increased mobilization of HSC adversely affects the engraftment and reconstitution of CXCR4-modified HSCs. The major ligand for CXCR4, stromal cell-derived factor 1 (SDF-1), also known as CXCL12, can be recognized by CXCR4 ([@B13]; [@B87]) and CXCR7 ([@B9]). An experimental study using the SDF-1 knockout mouse suggested that SDF-1 was involved in B cell development and bone-marrow myelopoiesis ([@B84]). However, the downstream signaling of CXCR4 using selected heterotrimeric G proteins has been thought to be independent of CXCR7. The unique pathway facilitated by CXCL12-CXCR4 may be a major hurdle for the development of CXCR4-modified hematopoietic stem cells as the resistant cell reservoir for HIV-1 infection.

Cell-Free Versus Cell-To-Cell Transmission
==========================================

The classical CD4, CCR5, or CXCR4 axis for cell-free HIV-1 entry has been extensively studied. In most of the gene editing studies performed with CCR5 or CXCR4, the amount of viral replication quantified was primarily from cell-free virus. While being able to stop cell-free infection is important, the method of cell-to-cell transmission should not be overlooked. Described below is how the field of broadly neutralizing antibodies have had mixed success with blocking cell-to-cell transmission and how a gene editing approach may be able to overcome some of those hurdles. In addition, the section below will discuss how HIV-1 can enter target cells through bulk endocytosis or from a macrophage phagocytosing an infected dying T-cell.

One of the promising therapeutic approaches to blocking HIV-1 infection is through the use of broadly neutralizing antibodies ([@B53]; [@B86]; [@B43]). The idea behind this approach is the same as a vaccine, stop the virus from entering cells. A multitude of studies have reported the successful prevention of multiple strains of virus from beginning the infection cycle ([@B124]). Now the field faces the question: can these antibodies be used to block the entirety of the quasispecies? If so, how long will the antibodies last in circulation ([@B8])? There are reports of modifying these antibodies to persist in the plasma making them effective for a longer period of time ([@B43]). While these reports are promising, these antibodies still degrade over time and if they fall below a certain threshold they no longer protect from HIV-1 infection. In addition, it has been shown that these broadly neutralizing antibodies have performed well neutralizing cell-free virus. However, blocking cell-to-cell transfer of virus has been much more difficult ([@B73]; [@B100]). A recent study characterized the differences between a number of broadly neutralizing antibodies and their ability to block cell-to-cell transmission of HIV-1. The results described how cell-to-cell transmission was not efficiently neutralized by antibodies. This study also included transmitter founder envelopes which showed a reduced ability to be neutralized during cell-to-cell transmission ([@B67]). An additional study was performed that was able to identify a few broadly neutralizing antibodies that were able to block cell-to-cell transmission to some degree ([@B73]). These antibodies included ones that target the CD4 binding site (NIH45-46, 3BNC60), and the V3 loop (10-1074, PGT121). Antibodies that targeted the V3 loop were effective against CCR5-utilizing virus but were ineffective against CXCR4-utilizng virus. As described in the previous section, being able to use gene editing technology would allow cells to become resistant to both CCR5- and CXCR4-utilizing viruses. Moreover, the concern of antibody half-life would be avoided, and the patient wouldn't need multiple infusions of antibody to block infection over a long period of time. While not experimentally tested, the idea of combining gene editing strategies with broad neutralizing antibodies could serve as a viable clinical option. While the broad neutralizing antibodies could neutralize cell-free virus, the gene edited cells could resist cell-to-cell transmission, blocking multiple routes of viral infection.

The ability to stop cell-to-cell transmission of HIV-1 is crucial because cell-to-cell transmission is up to 10-fold more efficient than cell-free transmission ([@B20]). Cell-to-cell transmission is in part more efficient due to the formation of a virological synapse between an infected cell and an uninfected cell ([@B14]). This synapse forms when a donor T cells comes into contact with an infected T-cell. The cells maintain close contact through actin rearrangement and LFA-1/ICAM-1 interactions. Once gp120 from the infected cell binds to CD4 on the donor cell, a cytosolic rearrangement is triggered that sequesters CCR5 and CXCR4 to the site of cellular contact. This enables the virus to infect the donor cell in a manner very difficult to block by neutralizing antibodies. This pitfall represented another advantage for using gene editing technologies to edit the co-receptors needed for HIV-1 entry. The virological synapse will still form between two cells but without the co-receptors (CCR5 or CXCR4) gp120 will not be able to undergo the conformational changes necessary to enter the uninfected cell. While cell-to-cell transmission has been shown to be more effective than cell-free transmission *in vitro*, the *in vivo* efficacy is still debated in the field. In light of this debate there have been a number of studies that have looked at how well antiretroviral compounds are able to block cell-to-cell transmission. It was shown that a number of NNRTIs, entry inhibitors, and protease inhibitors were able to effectively block cell-to-cell transmission. Moreover, the same study demonstrated how certain NRTIs were not able to effectively block cell-to-cell transmission highlighting the need for careful consideration when deciding on the best treatment options for patients ([@B3]). Moreover, there is considerable evidence to suggest that at the virological synapse, there are a large number of viral particles thereby increasing the probability of infection and a possible mechanism for overcoming antiretroviral therapy ([@B2]). An additional study utilized HIV-1-infected patient sera to determine if that sera was able to neutralize cell-free and cell-to-cell transmission. It was demonstrated that while patient sera was able to effectively neutralize cell-free transmission, it was only half as effective against cell-to-cell transmission ([@B22]). While the previous studies used *in vitro* systems, there has been a study that utilized humanized mouse models to study the kinetics of HIV-1 cell-to-cell transmission. This study highlighted that in an *in vivo* system, cell-to-cell transmission was occurring frequently and was more resistant to AZT than cell-free transmission in the lung of infected mice. It was also observed that cell-free and cell-to-cell transmission yielded very similar viral loads, indicating that cell-to-cell transmission is effective *in vivo* ([@B66]).

Another alternative entry mechanism for HIV-1 has been shown to be through a macrophage phagocytosing an infected T-cell ([@B10]). It is well established that macrophages phagocytose dead or dying cells. When a T-cell has been infected by HIV-1 it normally dies within 24--48 h ([@B32]). During this window of cell death, macrophages have been shown to engulf infected T cells. HIV-1 is then able to infect the macrophage through what has been shown to be a CD4/CCR5 dependent pathway. A study showed that monocyte-derived macrophages (MDMs) that were homozygous for the CCR5Δ32 mutation were resistant to infection from engulfing infected T cells ([@B10]). While HIV-1 has been shown to rely on CD4 and CCR5 when infecting macrophages from engulfed T cells, there is a CD4/CCR5 independent mechanism to infect macrophages. Previous studies have used the HIV-1 molecular clone NL4-3 without an envelope (NL4-3 -env) and assessed whether it could infect macrophages ([@B45]). Depending on the activation state of the macrophage, in this case, a classical M1 macrophage was able to become infected with an NL4-3 env while M0 and M2a macrophages showed little to no infection. It was hypothesized in this study that HIV-1 was utilizing an alternative endocytosis pathway to escape the endosome. This study also highlighted the point that while HIV-1 could gain access to activated M1 macrophages, viral replication was very limited as demonstrated by decreased luciferase expression from an NL4-3 luciferase construct. Although HIV-1 was endocytosed into the cell, escaping from the endosome proved to be very difficult.

Conclusion and Future Directions
================================

Antiretroviral therapy has transformed HIV-1 into a chronic but manageable disease. Research investigations are now focus on methods to develop a functional or sterilizing cure to prevent or further dampen HIV-1 disease. Gene editing technologies stand as a promising method to reach a functional or sterilizing cure with results both *in vitro* and *in vivo*. In addition, there are multiple clinical trials underway to evaluate how efficacious this therapy can be in human patients. While these newer approaches show promise, they are not without their own obstacles. In order to be a truly effective therapy, gene editing efficiency would need to be improved. Moreover, getting a large enough pool of successfully edited cells will be important for therapies not involving stem cells. The potential benefits of successful gene editing technologies have made them an attractive option for a next generation treatment for HIV-1 (Figure [3](#F3){ref-type="fig"}).
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Some of the necessary challenges to transforming gene editing techniques into an attractive curative HIV-1 treatment are common to all gene editing strategies. Efficient delivery of therapy to targeted tissues and suppression of off-target effects are two such challenges. Efforts to address these hurdles are underway.

The sequence length of the ZFN module (∼1 kb) is relatively small compared with TALEN (∼3 kb) and CRISPR/Cas9 systems (∼4 kb). This has been shown to be advantageous for vector-based delivery. However, limited DNA targets due to the restricted combination of Zinc finger protein (ZFP) and cytotoxicity due to off-target cleavages has hindered the development of ZFN-mediated therapy. Although TALEN has reduced cytotoxicity and increased design flexibility compared to ZFN, the size of TALEN has been a major challenge for vector-based delivery. Nonetheless, the rearrangement of the sequence recognition site on ZFN and TALEN for different target loci has been considered time-consuming and complicated. This complex process has provided a clear advantage to RNA-guided gene editing systems with respect to anti-HIV-1 therapeutic development. By changing the protospacer region on a sgRNA, the CRISPR/Cas9 system can be versatile enough to target most of the desired sequences in HIV-1 genomes. However, the size of SpCas9 (∼4 kb) has been a predominant issue for vector-based delivery. The suitable size of SaCas9 (∼3 kb) facilitates more efficient delivery into viral vectors that have a limited storage capacity \[[@B117]\]. This study has successfully edited CXCR4 in CD4^+^ T cells using *Staphylococcus aureus* Cas9 (SaCas9) and a lentiviral delivery system. Modified cells showed resistance to HIV-1 infection, which has provided a promising stepping stone for *in vivo* modification.

An additional challenge for any kind of gene editing strategy to target HIV-1 is centered on being able to locate and modify cells in different anatomical sites or modify precursor cells that are destined to traffic to tissue sites. This is an especially important consideration because the latent reservoir that HIV-1 develops has been shown to be located in multiple anatomical sites throughout the body. A recent study performed in rhesus macaques (RM) with SIV has illustrated that even when ART was administered there were sites of viral RNA-positive cellular staining in multiple organ systems ([@B37]; [@B27]). For any *in vivo* gene editing approach, a delivery system that can be transported to multiple sites will be highly beneficial. In addition, editing tissue resident cells will be vital to stopping reactivated virus from replicating and expanding the reactivation event. While gene editing systems have been used *in vivo*, it hasn't been fully elucidated whether tissue resident cells have been successfully edited, although it has been shown that editing hematopoietic stem/progenitor cells (HSPCs) with a ZFN targeting CCR5 were able to engraft into multiple tissue compartments. These edited cells were then able to re-fill virus depleted CD4+ central memory T cells in the gut of infected NHPs ([@B92]).

As it is currently developing, co-receptor editing for HIV-1 infection will likely not target all latent viral reservoirs, nor the entirety of the peripheral blood reservoir. Tissue resident cells for example would be less likely to be effectively targeted. Furthermore, it will probably not be able to efficiently target all potential mechanisms of viral propagation within the peripheral blood reservoir. As such, concerns about the efficacy of this treatment as a curative strategy are valid. However, one could envision that co-receptor editing could be destined to be developed into a complimentary therapeutic approach, further restricting the replication of HIV-1 in conjunction with existing ART regimens and other forms of anti-HIV-1 CRISPR/Cas9 therapeutic strategies. However, pursuit of this technology as a curative strategy remains optimistic. The cautiously accepted cure of the "Berlin Patient" has been regarded as a direct result of a CCR5-deficient bone marrow transplant. In the absence of a deeper understanding of the mechanism for the "cure" of the "Berlin Patient," ablation of the CCR5 receptor in CD4 T cells has become the focal point of research in this area of investigation. Why the absence of the CCR5 receptor in transplanted tissue should result in non-progressive HIV-1 replication for this patient remains an interesting question. Reproducing this medical outcome remains a critical step toward finding an answer.

One approach to the reduction of off-target effects has been to directly deliver Cas9/sgRNA ribonucleoproteins (Cas9 RNPs) to infected cells rather than delivering plasmids. Delivery of the Cas9 RNPs addresses the potential for unwanted CRISPR/Cas9 activity after its intended substrate is consumed. The studies focused on Cas9 protein engineering have provided substantial improvements to minimize off-target effects. A series of SpCas9 mutants have been identified that facilitate reduced off-target effects on undesired loci including a D1135E variant, eSpCas9 and SpCas9-HF1 ([@B62], [@B61]; [@B105]). However, a fitness cost of on-target efficiency has been found on most of these engineered proteins. A recent report that examined the RNP delivery method with R691A SpCas9 mutant in human HSPCs showed minimal off-target editing while retaining optimal on-target activity ([@B113]). Cas9 RNPs provide a distinct advantage because once they have bound and cleaved their target they are degraded, allowing for maximization of on target cleavage while minimizing off target effects. Cas9 RNPs were used to disrupt CXCR4 expression in human CD4+ T cells *in vitro* ([@B101]). There have also been reports of using nanoparticles for delivery of Cas9-RNPs into cells ([@B80]).

Minimization of the number of off-target cleavage events has been of paramount importance in gene editing. In this regard, we are not aware of any high-throughput studies that have demonstrated any off-target cleavage events during CCR5 ablation. Furthermore, to date, we are not aware of any studies that have indicated any downstream off-target effects of off-target cleavage events (e.g., cell death) at a population level for treated cells. Even so, careful screening for off-target cleavage will continue to be important in this context. Even in an *ex vivo* treatment, the changes introduced in cells will be sustained in modified cells during subsequent cultivation *in vitro* or after transplanted cells into experimental animals. Furthermore, any broadly applicable treatment dependent on sequence similarity will demand consideration of genetic diversity for large scale application. Techniques such as recently published unbiased sequencing techniques capable of detecting the sequence location of cleavage events in targeted cells will be critical to validate gene editing therapies ([@B110], [@B109]).

There have been important recent advances in therapeutic strategies focused on ablation of the HIV-1 receptor and co-receptors but there is still much to be done to refine this approach with respect to a reliable therapeutic application. It is likely that targeting the receptors to prevent acute viral infection or minimize HIV-1 disease emanating from activation of latent virus within tissue reservoirs will require a combined approach with other strategies that engage a more robust immune response in conjunction with targeting existing or yet to be identified aspects of the viral life cycle.
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